104 related articles for article (PubMed ID: 7332603)
1. Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs.
Franceschini G; Poli A; Catapano AL; Gatti E; Sirtori M; Gianfranceschi G; Sirtori CR
Atherosclerosis; 1981; 40(3-4):245-55. PubMed ID: 7332603
[TBL] [Abstract][Full Text] [Related]
2. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
[TBL] [Abstract][Full Text] [Related]
5. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
6. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
[TBL] [Abstract][Full Text] [Related]
7. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
Brook JG; Lavy A; Aviram M; Zinder O
Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
[TBL] [Abstract][Full Text] [Related]
8. Effect of dietary treatment on the lipid, lipoprotein and fatty acid compositions in type IV familial hypertriglyceridemia.
Agheli N; Cloarec M; Jacotot B
Ann Nutr Metab; 1991; 35(5):261-73. PubMed ID: 1776822
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of gemfibrozil on lipoprotein metabolism.
Saku K; Gartside PS; Hynd BA; Kashyap ML
J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
[TBL] [Abstract][Full Text] [Related]
10. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
[TBL] [Abstract][Full Text] [Related]
11. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Artery; 1980; 8(2):113-9. PubMed ID: 7458676
[TBL] [Abstract][Full Text] [Related]
12. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
13. Experimental studies on pharmacology, metabolism and toxicology with tiadenol-disulfoxide. Dissociation of lipid lowering effects and the induction of peroxisomal and microsomal drug-metabolizing enzymes.
Maffei Facino R; Carini M; Tofanetti O; Casciarri I; Longoni E
Arzneimittelforschung; 1987 Jun; 37(6):682-91. PubMed ID: 3663266
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities of composition and of in vitro lipolysis products of human small very low density lipoproteins in hypertriglyceridemia.
Tornvall P; Hamsten A; Carlson LA
Atherosclerosis; 1990 May; 82(1-2):125-35. PubMed ID: 2360914
[TBL] [Abstract][Full Text] [Related]
15. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
16. Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial.
Harris WS; Dujovne CA; Zucker M; Johnson B
Ann Intern Med; 1988 Sep; 109(6):465-70. PubMed ID: 3166357
[TBL] [Abstract][Full Text] [Related]
17. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Vessby B; Lithell H; Gustafsson IB; Borberg J
Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
[TBL] [Abstract][Full Text] [Related]
18. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia.
Taskinen MR; Nikkilä EA
Atherosclerosis; 1988 Feb; 69(2-3):249-55. PubMed ID: 3279968
[TBL] [Abstract][Full Text] [Related]
19. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Orö L
Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
[TBL] [Abstract][Full Text] [Related]
20. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
Artery; 1985; 12(6):363-81. PubMed ID: 4051756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
